Edition:
United States

People: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.52EUR
4:34am EDT
Change (% chg)

€0.06 (+0.57%)
Prev Close
€11.45
Open
€11.77
Day's High
€11.77
Day's Low
€11.52
Volume
28,425
Avg. Vol
214,511
52-wk High
€16.20
52-wk Low
€10.00

de Fougerolles, Antonin 

Dr. Antonin (Tony) de Fougerolles, Ph.D., is Chief Scientific Officer of Ablynx NV. since October 2013. He has more than 15 years of biotech research and development experience and knowledge in building out pipelines and expanding platform technologies. Prior to joining the Company, he was Chief Scientific Officer at Moderna Therapeutics where he led the Science Department. Previously, he was Chief Scientific Officer at Tolerx Incand, and prior to that he served on the management team of Alnylam Pharmaceuticals as Vice President, Research, Immunology, Metabolic, and Viral Disease from 2003 to 2010. He also served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.) from 1998 to 2003, where he worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. He earned his Doctorate in Philosophy degree in Immunology from Harvard University, and was an Arthritis and Rheumatism Council Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --